Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-505 in hyperphosphatemia in CKD patients on hemodialysis
NCT04551300Phase 2Completed
- Sponsor
- Alebund Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AP301 in hyperphosphatemia (5 arms), sponsored by Alebund Pharmaceuticals. Primary endpoint: Serum phosphorus change from baseline to end of treatment at 6 weeks. Started Oct 2020; status: completed.
02
Drugs
AP301
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT04551300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551300.